




PHARMACEUTICAL 2019

NANOMIX Corp
Rank 335 of 363





PHARMACEUTICAL 2019

NANOMIX Corp
Rank 335 of 363

The relative strengths and weaknesses of NANOMIX Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NANOMIX Corp compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 35% points. The greatest weakness of NANOMIX Corp is the variable Assets, Current, reducing the Economic Capital Ratio by 169% points.

The company's Economic Capital Ratio, given in the ranking table, is -306%, being 342% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	922
Cost of Goods Sold	0
Intangible Assets	515
Liabilities, Current	4,659
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,390
Other Liabilities	926
Other Net Income	-322
Other Revenues	32
Property and Equipment	2.1
Research and Development	183
Selling, General and Administrative Expense	1,738

Output Variable	Value in 1000 USD
Assets	1,439
Liabilities	5,585
Expenses	3,311
Revenues	32
Stockholders Equity	-4,146
Net Income	-3,601
Comprehensive Net Income	-3,601
Economic Capital Ratio	-306%